Form 4: Celldex Therapeutics Director Acquires Stock Options

Director Herbert J. Conrad acquired 16,500 non-qualified stock options in Celldex Therapeutics on June 13, 2024, according to a Form 4 filing.

Summary

• Herbert J. Conrad, a director of Celldex Therapeutics, acquired 16,500 non-qualified stock options on June 13, 2024.
• The options were granted pursuant to the company's 2021 Omnibus Equity Incentive Plan.
• The exercise price of the options is $36.43.
• The options become exercisable on June 13, 2025, and expire on June 13, 2034.
• Following the transaction, Conrad directly owns 16,500 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating a director's acquisition of stock options, which is neither particularly positive nor negative.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment, as it may signal confidence in the company's future.

Key Dates